• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Finding suitable targets is the major obstacle to cancer gene therapy.

作者信息

Rosenberg Steven A

出版信息

Cancer Gene Ther. 2014 Feb;21(2):45-7. doi: 10.1038/cgt.2014.3.

DOI:10.1038/cgt.2014.3
PMID:24535159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6354240/
Abstract
摘要

相似文献

1
Finding suitable targets is the major obstacle to cancer gene therapy.寻找合适的靶点是癌症基因治疗的主要障碍。
Cancer Gene Ther. 2014 Feb;21(2):45-7. doi: 10.1038/cgt.2014.3.
2
Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.嵌合抗原受体T细胞的区域输注以克服实体瘤免疫治疗的障碍
J Vasc Interv Radiol. 2018 Jul;29(7):1017-1021.e1. doi: 10.1016/j.jvir.2018.03.001.
3
Adoptive cell therapy: Honing that killer instinct.过继性细胞疗法：磨砺杀手本能。
Nature. 2013 Dec 19;504(7480):S13-5. doi: 10.1038/504S13a.
4
Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modeling.T细胞受体工程化淋巴细胞的过继性细胞转移：近期模型研究的经验教训
Future Oncol. 2010 Nov;6(11):1671-3. doi: 10.2217/fon.10.137.
5
Adoptive transfer of virus-specific and tumor-specific T cell immunity.病毒特异性和肿瘤特异性T细胞免疫的过继转移。
Curr Opin Immunol. 2009 Apr;21(2):224-32. doi: 10.1016/j.coi.2009.02.010. Epub 2009 Mar 21.
6
Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors.通过肿瘤反应性受体的基因转移将 T 细胞重新靶向癌症。
Expert Opin Biol Ther. 2009 May;9(5):579-91. doi: 10.1517/14712590902887018.
7
Chimeric T-cell receptors for the targeting of cancer cells.用于靶向癌细胞的嵌合T细胞受体。
Acta Haematol. 2003;110(2-3):154-9. doi: 10.1159/000072465.
8
The promise and potential pitfalls of chimeric antigen receptors.嵌合抗原受体的前景与潜在风险。
Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25.
9
Adoptive transfer of T-cell immunity.
Trends Immunol. 2002 May;23(5):264-9. doi: 10.1016/s1471-4906(02)02219-6.
10
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.嵌合抗原受体修饰 T 细胞治疗实体瘤：现状与展望。
Sci China Life Sci. 2016 Apr;59(4):360-9. doi: 10.1007/s11427-016-5025-6. Epub 2016 Mar 11.

引用本文的文献

1
Preclinical Evaluation of a Near-Infrared Labelled Antibody Targeting the Tumour Associated Xenoantigen N-Glycolyl-Neuraminic Acid GM3 Ganglioside.靶向肿瘤相关异种抗原N-羟乙酰神经氨酸GM3神经节苷脂的近红外标记抗体的临床前评估
Mol Imaging Biol. 2025 Jun 17. doi: 10.1007/s11307-025-02026-z.
2
Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy.解锁凋亡途径：克服 CAR-T 细胞疗法中的肿瘤耐药性。
Cancer Med. 2024 Oct;13(19):e70283. doi: 10.1002/cam4.70283.
3
CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects.基于嵌合抗原受体 T 淋巴细胞的细胞疗法；自杀基因在机制论证、应用和生物安全性增强方面的作用：消除副作用的新机遇。
Front Immunol. 2024 Jul 18;15:1333150. doi: 10.3389/fimmu.2024.1333150. eCollection 2024.
4
Adoptive cell therapy for cancer treatment.用于癌症治疗的过继性细胞疗法。
Exploration (Beijing). 2023 Jul 2;3(4):20210058. doi: 10.1002/EXP.20210058. eCollection 2023 Aug.
5
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.个体化、多靶点、过继细胞治疗（IMA101）的可行性和安全性：晚期转移性癌症患者的首次人体临床试验。
Cancer Immunol Res. 2023 Jul 5;11(7):925-945. doi: 10.1158/2326-6066.CIR-22-0444.
6
Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells.抗凋亡蛋白c-FLIP降低嵌合抗原受体T细胞的抗肿瘤活性。
Cancers (Basel). 2022 Oct 4;14(19):4854. doi: 10.3390/cancers14194854.
7
Navigating CAR-T cells through the solid-tumour microenvironment.CAR-T 细胞在实体瘤微环境中的行进。
Nat Rev Drug Discov. 2021 Jul;20(7):531-550. doi: 10.1038/s41573-021-00189-2. Epub 2021 May 10.
8
The SR-B1 Receptor as a Potential Target for Treating Glioblastoma.SR-B1受体作为治疗胶质母细胞瘤的潜在靶点。
J Oncol. 2019 Jun 3;2019:1805841. doi: 10.1155/2019/1805841. eCollection 2019.
9
More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?欲速则不达：公私合作能否推动细胞免疫疗法发展？
Front Med (Lausanne). 2017 Aug 16;4:134. doi: 10.3389/fmed.2017.00134. eCollection 2017.
10
Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.模块化构建的合成颗粒酶B分子可用于研究细胞内蛋白酶以实现靶向细胞毒性。
ACS Synth Biol. 2017 Aug 18;6(8):1484-1495. doi: 10.1021/acssynbio.6b00392. Epub 2017 May 22.

本文引用的文献

1
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.接受针对 Epstein-Barr 病毒潜伏膜蛋白的自体细胞毒性 T 淋巴细胞治疗的淋巴瘤患者获得持续完全缓解。
J Clin Oncol. 2014 Mar 10;32(8):798-808. doi: 10.1200/JCO.2013.51.5304. Epub 2013 Dec 16.
2
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.鉴定一种源自肌联蛋白的 HLA-A1 呈递肽作为工程化 MAGE A3 定向 T 细胞的交叉反应靶标。
Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034.
3
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.免疫靶向成纤维细胞激活蛋白触发多能骨髓基质细胞和恶病质的识别。
J Exp Med. 2013 Jun 3;210(6):1125-35. doi: 10.1084/jem.20130110. Epub 2013 May 27.
4
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.从外显子组测序数据中挖掘被过继转移的肿瘤反应性 T 细胞识别的突变抗原。
Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.
5
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.用表达抗 CD19 嵌合抗原受体的 T 细胞治疗 B 细胞癌。
Nat Rev Clin Oncol. 2013 May;10(5):267-76. doi: 10.1038/nrclinonc.2013.46. Epub 2013 Apr 2.
6
Cancer genome landscapes.肿瘤基因组图谱。
Science. 2013 Mar 29;339(6127):1546-58. doi: 10.1126/science.1235122.
7
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.抗 MAGE-A3 TCR 基因治疗后的癌症消退和神经毒性。
J Immunother. 2013 Feb;36(2):133-51. doi: 10.1097/CJI.0b013e3182829903.
8
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma.通过针对 EGFRvIII 的基因修饰 T 细胞识别神经胶质瘤干细胞和开发神经胶质瘤过继细胞治疗。
Hum Gene Ther. 2012 Oct;23(10):1043-53. doi: 10.1089/hum.2012.041. Epub 2012 Sep 24.
9
Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.细胞转移免疫疗法治疗转移性实体瘤——临床医生需要了解的知识。
Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116.
10
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.采用 T 细胞转移免疫疗法治疗转移性黑色素瘤的大量预处理患者中持久的完全应答。
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. doi: 10.1158/1078-0432.CCR-11-0116. Epub 2011 Apr 15.